identifying novel digital measures for fatigue and sleep disturbances that will provide more objective, sensitive and reliable measures of the severity and impact of these symptoms in the person’s normal surrounding.
one year longitudinal study with approximately 2000 subjects will be conducted
Participants with neurological or immunological disorders from various countries will be screened and recruited
Participants with neurological or immunological disorders from various countries will be screened and recruited
All participants will be given a combination of 2-4 digital devices for use in their own environment for several periods
Data on fatigue, sleep, selected activities of daily living and other relevant contextual information will be collected by smartphone several times a day while using the devices
In order to establish which devices are suitable for use, complex data analysis will be performed
The devices that met the criteria will be considered for future use in clinical trials
The novel clinically validated digital endpoint will be able to:
One of the ways we ensure that the patient voice is heard and put at the centre of the project in all its stages is by having monthly meetings with representatives of several patients organisations in
We are pleased to welcome Ioannis Pandis as the Interim Project Lead for IDEA-FAST, who is taking over the role from Fred Baribaud. Ioannis is already contributing to the project as the Industry Lead for
The Innovative Medicines Initiative (IMI) has shared the latest joint vision from MOBILISE-D and IDEA-FAST to strengthen R&D in the area of remote monitoring! Read the news here: https://www.imi.europa.eu/news-events/newsroom/digital-biomarkers-initiative-help-researchers-navigate-new-reality-roles
The 2nd General Assembly was held as a virtual meeting on 8th – 9th March 2021, with around 130 participants from all partners as well as external members of the Scientific Advisory Board and the Patient Specialist Advisory
Mobilise-D is working on digital mobility assessment in chronic obstructive pulmonary disease (COPD), Parkinson’s disease (PD), multiple sclerosis (MS) and recovery from proximal femoral fracture (PFF). IDEA-FAST is working to identify digital endpoints to assess
Mobilise-D and IDEA-FAST, two IMI projects that aim to develop real-world digital outcomes, have announced their plan to collaborate, to bring synergy and increase the impact and benefits of the digital health technologies developed by
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.
